Advicor is owned by Abbvie.

Advicor contains Lovastatin; Niacin.

Advicor has a total of 9 drug patents out of which 9 drug patents have expired.

Expired drug patents of Advicor are:

• US6676967
• US7998506
• US6818229
• US6746691
• US6129930
• US7011848
• US6406715
• US6080428
• US6469035

Advicor was authorised for market use on 17 December, 2001.

Advicor is available in tablet, extended release;oral dosage forms.

Advicor can be used as intermediate rel nicotinic acid formulations having unique urinary metab profiles resulting from absorption profiles of nicotinic acid from the intermediate nicotinic acid formulations,suitable for tx hyperlipidemia following qd dosing, treatment of hypercholesterolemia by dosing once per day in the evening or at night, an intermediate release nicotinic acid formulation suitable for oral administration once-a-day as a single dose for treating hyperlipidemia without causing drug-induced hepatotoxicity or elevations in uric acid or glucose or both, treatment of hypertriglyceridemia by dosing once per day in the evening or at night, through reduction of ldl-c, tc, tg, lp(a), and increase of hdl-c, a method of using a nicotinic acid formulation to reduce elevated tc, ldl-c and tg levels, and raise hdl-c levels in patients with hyperlipidemia, method of treating hyperlipidemia with nicotinic acid by dosing once per day in the evening or at night, a method of reducing the capacity of extended release nicotinic acid to provoke a flushing reaction by pretreating an individual with a flush inhibiting agent prior to the administration of the extended release nicotinic acid, a method of reducing flush in an individual being treated for a lipidemic disorder and effectively treating the lipidemic disorder.

The generics of Advicor are possible to be released after 15 March, 2018.